About Deepcell
Deepcell focuses on biotechnology for cell analysis and sorting, primarily through its REM-I platform. This platform combines label-free imaging, deep learning, and microfluidics to analyze and categorize cells based on their shape and structure, providing detailed data for researchers. Unlike competitors, Deepcell's technology offers a high-dimensional quantitative readout and deep characterization of cells, making it valuable for pharmaceutical and academic research. The company's goal is to lead in cell analysis and sorting, providing insights that enhance scientific understanding.
Sunnyvale, CaliforniaHeadquarters
2015Year Founded
$173.1MTotal Funding
LATE_VCCompany Stage
Data & Analytics, AI & Machine Learning, BiotechnologyIndustries
11-50Employees
Risks
Emerging competition from companies like Berkeley Lights could impact Deepcell's market share.
Rapid technological advancements may require costly updates to Deepcell's REM-I platform.
Potential ethical concerns and regulatory scrutiny could slow product adoption.
Differentiation
Deepcell's REM-I platform combines label-free imaging with deep learning for cell analysis.
The company uses advanced microfluidics for precise cell sorting and analysis.
Deepcell's AI-driven technology provides high-dimensional quantitative readouts of individual cells.
Upsides
Deepcell is raising $80M to expand and accelerate product development.
Demand for label-free imaging technologies is increasing, aligning with Deepcell's offerings.
AI in translational research is expanding, enhancing Deepcell's value proposition.
Funding
Total raised$173.15 M
Latest valuation$400.00 M
StageLATE_VC
LATE VC
9/30/2022$80
$400.00 MSERIES A
11/30/2020$20
$100.00 MSEED
1/31/2018$5
$25.00 M